The Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors in the Treatment of HIV Infections (AIDS)
The Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors in the Treatment of HIV Infections (AIDS)
复制标题
DOI：
10.1016/b978-0-12-405880-4.00009-3
复制
发表时间：
2013-01-01
期刊：
影响因子：
--
通讯作者：
De Clercq, Erik
中科院分区：
文献类型：
--
作者：
De Clercq, Erik
目前用于治疗HIV感染（AIDS）的大多数药物属于以下三类：核苷类逆转录酶抑制剂（NRTI）、非核苷类逆转录酶抑制剂（NNRTI）和蛋白酶抑制剂（PI）。目前，有7种NRTI、5种NNRTI和10种PI获批用于临床。从以下角度讨论这些药物：㈠化学式; ㈡作用机制; ㈢药物组合; ㈣临床方面; ㈤接触前预防; ㈥预防母婴传播; ㈦儿童使用; ㈧毒性; ㈨坚持使用（依从性）;（x）耐药性;（xi）（临床前）开发中的新NRTI、NNRTI或PI;和（xii）疾病“治愈”的前景。
The majority of the drugs currently used for the treatment of HIV infections (AIDS) belong to either of the following three classes: nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs). At present, there are 7 NRTIs, 5 NNRTIs, and 10 PIs approved for clinical use. They are discussed from the following viewpoints: (i) chemical formulae; (ii) mechanism of action; (iii) drug combinations; (iv) clinical aspects; (v) preexposure prophylaxis; (vi) prevention of mother-to-child transmission; (vii) their use in children; (viii) toxicity; (ix) adherence (compliance); (x) resistance; (xi) new NRTIs, NNRTIs, or PIs in (pre)clinical development; and (xii) the prospects for a "cure" of the disease.